SAN DIEGO--(BUSINESS WIRE)--Bio-Matrix Scientific Group’s (OTCBB:BMSN) announced today that it has retained a private grant research and development firm to aggressively pursue both private and public sector grant funding of research in the area of Stem Cell Therapy for Chronic Obstructive Pulmonary Disease (COPD) conducted by Entest BioMedical, Inc. (OTCBB:ENTB). Entest BioMedical, Inc. is a publicly traded, majority owned subsidiary of Bio-Matrix.
